Our Company / Our Legacy
A leading role
in the history of pharmaceutical industry,
1948, the time of our foundation, coincides with a crucial moment in human history: the year in which the Universal Declaration of Human Rights was signed. In that same year, in Bologna, Marino Golinelli, just out of college with a degree in pharmaceutical sciences, establishes the company Biochimici Alfa, later to become Alfa Wassermann. The company grows steadily, year after year, thanks to a strong development strategy and a rigorous acquisition plan.
2015-2017. Alfasigma, an all-Italian pharmaceutical company, was founded: the outcome of the union between the Alfa Wassermann and Sigma-Tau groups. The new company immediately gains a spot in the top tier of private players in the pharmaceutical industry, capitalising on the know-how, potential and specialisation of the companies from which it originated.
Launch of the anti-malarial drug Eurartesim, later to be registered in endemic countries of Africa and Asia and today distributed in 32 African countries.
The acquisition plan started 10 years earlier is at its highest point, bringing companies from various European and extra-European countries to the group: United States, China, Russia, Mexico, Tunisia, France, Czech Republic, Slovakia, Holland, Poland, Romania.
Alfasigma is created by the aggregation of Alfa Wassermann and Sigma-Tau: the activities of two of the most important privately held pharmaceutical groups in Italy converge through a major industrial project.
Alfasigma, the outcome of the union between the Alfa Wassermann and Sigma-Tau groups, an all-Italian pharmaceutical company, immediately become one of the top five operators in the pharmaceutical sector in Italy.
In the same year, Alfasigma launches the new financial plan, aimed at boosting development in the area of specialty drugs and the international presence of the group.
Construction begins in Pomezia (Rome, Italy) on the new Pharmaceutical Technological Development Centre (La.Bio 4.0), which solidifies the group’s R&D footprint along with the centre in Bologna (Italy).
With the explosion of the COVID-19 pandemic, Alfasigma proceeds to lock down its administrative offices, while production and R&D continue their activities on-site. Activities continue in remote working mode for over two months, until 4 May, start date of Phase 2 under the aegis of the #RESTART project.